Thymosin β10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 4
Abstract
Introduction and aim. 5-Fluorouracil (5-FU) is the most commonly used chemotherapeutic drug in the treatment of cholangiocarcinoma (CCA). Since development of drug resistance to 5-FU in CCA patients is the primary cause of treatment failure, a better understanding of the mechanism of drug resistance of this cancer is essential to improve the efficacy of 5-FU in CCA therapy. Material and methods. A 5-FU resistant CCA cell line (M214-5FUR) for a comparative chemo-resistancestudy was established. Real time RT-PCR was used to determine gene expression levels. Cell cytotoxicity was measured by theMTT assay. Protein expression levels were detected by the immunofluorescene method. Results. It was found that 5-FU resistance was associated with the overexpression of T?10 in CCA cell lines. 5-FU treatment at various concentrations induced the expressions of T?10 and ABC transporters (ABCB1, ABCG2 ABCA3) in two CCA cell lines, KKU-M055 and KKU-M214. M214-5FUR, a 5-FU-resistant cell line, exhibited a 5-FU resistant phenotype with a 16-fold extremely high expression of T?10 and ABC transporters, as compared to the parental cells, KKU-M214. siRNA targeted to T?10 significantly reduced expression of ABC transporters tested in the M214-5FUR cells (P < 0.05). Conclusions. The present novel findingsof T?10 connected with drug resistance as shown in this study provides a new insight for the therapeutic value of T?10 as a predictive biomarker of 5-FU chemoresistance. Inhibiting T?10 may be a valuable adjunct for suppression of ABC transporters and sensitizing chemotherapy treatment, especially 5-FU in CCA patients.
Authors and Affiliations
Sirinapa Sribenja, Nichapavee Natthasirikul, Kulthida Vaeteewoottacharn, Kanlayanee Sawanyawisuth, Chaisiri Wongkham, Patcharee Jearanaikoon, Sopit Wongkham
Keywords
Related Articles
- EP ID EP78603
- DOI 10.5604/16652681.1203155
- Views 145
- Downloads 0
Long-term follow-up of hepatitis C virus-positive patients with persistently normal serum transaminases
[b]Material and methods.[/b] This study prospectively evaluated the progression of liver disease in a group of anti-HCV-positive patients with persistently normal ALT levels (PNALT) who were HCV-RNA positive. Patients se...
Efficacy of triple therapy with thymalfasin, peginterferon α-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders
Background/Aims: Thymalfasin has shown efficacy in the treatment of chronic HCV infection. The aim of this study was to evaluate the efficacy and tolerability of triple therapy with thymalfasin, peginterferon α-2a (PEG-I...
Algorithm for Screening of Adrenal Function in Stable Patients with Cirrhosis
Introduction and aims. Adrenal insufficiency (AI) is common in patients with cirrhosis. We aimed to assess the presence of AI in stable patients with cirrhosis using the gold-standard insulin tolerance test (ITT) and to...
Current and future treatment options for HCV
Aim of antiviral therapy of patients with chronic hepatitis C is the sustained elimination of the hepatitis C virus (HCV). The standard of care (SOC) is peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks i...
Hepatitis B virus Reactivation During Steroid Treatment of IgG4-Related Disease
-